Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

<p>Supplementary TablesSupplementary Table 1: Patient and tumor sample informationSupplementary Table 2: Tumor mutation burdenSupplementary Table 3: Unfiltered whole exome sequencing mutation analysisSupplementary Table 4: Filtered whole exome sequencing mutation analysisSupplementary Table 5:...

Szczegółowa specyfikacja

Zapisane w:

Opis bibliograficzny
1. autor:	H. Josh Jang (15206898) (author)
Kolejni autorzy:	Galen Hostetter (15053070) (author), Alexander W. Macfarlane (15206901) (author), Zachary Madaj (15206904) (author), Eric A. Ross (15019395) (author), Toshinori Hinoue (15206907) (author), Justin R. Kulchycki (15206910) (author), Ryan S. Burgos (15206913) (author), Mahvish Tafseer (15206916) (author), R. Katherine Alpaugh (15206919) (author), Candice L. Schwebel (15206922) (author), Rutika Kokate (15206925) (author), Daniel M. Geynisman (15206928) (author), Matthew R. Zibelman (15206931) (author), Pooja Ghatalia (15206934) (author), Peter W. Nichols (15206937) (author), Woonbok Chung (15206940) (author), Jozef Madzo (14923007) (author), Noah M. Hahn (15206943) (author), David I. Quinn (15012291) (author), Jean-Pierre J. Issa (15109358) (author), Michael J. Topper (15206946) (author), Stephen B. Baylin (15045804) (author), Hui Shen (10996894) (author), Kerry S. Campbell (9724036) (author), Peter A. Jones (14941116) (author), Elizabeth R. Plimack (15044781) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Genitourinary Cancers Bladder cancer Immunotherapy Checkpoint blockade Small Molecule Agents Epigenetic-targeted agents
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Napisz pierwszy komentarz!

Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Podobne zapisy